The monoclonal antibody lanadelumab demonstrated long-term efficacy for patients with hereditary angioedema (HAE) who had received prophylactic lanadelumab for ≥12 months, according to findings from the post hoc analysis of the phase III HELP OLE* study presented at ACAAI 2021.
In post hoc analyses of the phase III SINUS-24 and SINUS-52 trials, the monoclonal antibody dupilumab continued to render improvements for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), as well as among those with comorbid asthma regardless of asthma characteristics.
Women who have a documented history of penicillin allergy should undergo allergy tests during pregnancy to avoid exposure to potentially less effective broad-spectrum antibiotics, according to a small study presented at ACAAI 2021.
Despite guidelines advocating earlier introduction of peanut in infants to avoid peanut allergy, adherence to these guidelines among children’s primary care providers (PCPs) remains suboptimal, according to a study from the US presented at ACAAI 2021.
People who had an allergic response to the first dose of COVID-19 vaccination or who believe they will have an allergy to vaccination should not let their worries delay getting vaccinated — as most of them can still be fully vaccinated safely, suggest studies presented at ACAAI 2021.